Date: 2016-12-22
Type of information: Milestone
Compound: antisense drugs
Company: Isis Pharmaceuticals (USA - CA) - Janssen Biotech, a J&J company (USA - NJ)
Therapeutic area: Autoimmune diseases - Gastrointestinal diseases - Digestive diseases
Type agreement: R&D
Action mechanism:
Disease: autoimmune disorders of the gastrointestinal (GI) tract
Details: * On January 5, 2015, Isis Pharmaceuticals announced that the company has entered into a global collaboration with Janssen Biotech, to discover and develop antisense drugs to treat autoimmune disorders of the gastrointestinal (GI) tract. The collaboration brings together Isis' RNA-targeted technology platform and the expertise of Janssen in autoimmune disorders and therapeutic formulation to discover and develop antisense drugs that can be locally administered, including oral delivery, to treat autoimmune disorders in the GI tract.
Financial terms: Under the terms of the agreement, which covers three programs, Isis will receive $35 million in upfront payments, including a payment to initiate human lead optimization on the first collaboration target. Isis is eligible to receive nearly $800 million in development, regulatory and sales milestone payments and license fees for these programs. In addition, Isis will receive tiered royalties that on average are double-digits on sales from any product that is successfully commercialized. Janssen has the option to license a drug from each of the programs once a development candidate is identified. If Janssen exercises its option, it will assume global development, regulatory and commercialization responsibilities.
Latest news: * On December 22, 2016, Ionis Pharmaceuticals announced that it has earned $5 million milestone payment from Janssen Biotech, associated with the validation of an undisclosed target to treat patients with a gastrointestinal (GI) autoimmune disease. Under the collaboration, Ionis and Janssen will continue to evaluate the target with the goal of advancing an antisense drug into development. Under the terms of the agreement, which covers three programs, Ionis is eligible to receive nearly $800 million in development, regulatory and sales milestone payments and license fees. In addition, Ionis will receive tiered royalties that on average are double-digits on sales from any product that is successfully commercialized.
